- Home
- VOXR vs IPHA Comparison
VOXR vs IPHA Comparison
Compare VOXR & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- IPHA
- Stock Information
- Founded
- VOXR 2014
- IPHA 1999
- Country
- VOXR United States
- IPHA France
- Employees
- VOXR N/A
- IPHA N/A
- Industry
- VOXR Precious Metals
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- VOXR Basic Materials
- IPHA Health Care
- Exchange
- VOXR Nasdaq
- IPHA Nasdaq
- Market Cap
- VOXR 187.3M
- IPHA 160.1M
- IPO Year
- VOXR N/A
- IPHA 2019
- Fundamental
- Price
- VOXR $3.54
- IPHA $1.94
- Analyst Decision
- VOXR
- IPHA Hold
- Analyst Count
- VOXR 0
- IPHA 2
- Target Price
- VOXR N/A
- IPHA $2.00
- AVG Volume (30 Days)
- VOXR 288.2K
- IPHA 15.1K
- Earning Date
- VOXR 11-05-2025
- IPHA 09-17-2025
- Dividend Yield
- VOXR 1.41%
- IPHA N/A
- EPS Growth
- VOXR N/A
- IPHA N/A
- EPS
- VOXR N/A
- IPHA N/A
- Revenue
- VOXR $10,771,473.00
- IPHA $14,839,695.00
- Revenue This Year
- VOXR $22.49
- IPHA $350.96
- Revenue Next Year
- VOXR $10.55
- IPHA $32.92
- P/E Ratio
- VOXR N/A
- IPHA N/A
- Revenue Growth
- VOXR N/A
- IPHA N/A
- 52 Week Low
- VOXR $2.21
- IPHA $1.29
- 52 Week High
- VOXR $3.79
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- VOXR 52.96
- IPHA 38.72
- Support Level
- VOXR $3.45
- IPHA $1.93
- Resistance Level
- VOXR $3.70
- IPHA $2.19
- Average True Range (ATR)
- VOXR 0.13
- IPHA 0.11
- MACD
- VOXR -0.01
- IPHA -0.01
- Stochastic Oscillator
- VOXR 40.54
- IPHA 13.19
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.